Claritev Corporation Announces Fourth Quarter 2025 Earnings Conference Call
Claritev and Kinetiq Health Enter Into Strategic Agreement to Strengthen Cost Management and Advance Claims Surveillance and Diagnostic Certainty [Yahoo! Finance]
Claritev and Kinetiq Health Enter Into Strategic Agreement to Strengthen Cost Management and Advance Claims Surveillance and Diagnostic Certainty
Claritev (NYSE:CTEV) was upgraded by analysts at Wells Fargo & Company to a "hold" rating.
Claritev (NYSE:CTEV) is now covered by analysts at Guggenheim. They set a "buy" rating and a $43.00 price target on the stock.